Chronic prostatic inflammation (CPI) could be a cause of symptomatic or complicated benign prostatic hyperplasia (BPH). In previous in vitro and in vivo studies, Hexanic Extract of Serenoa repens (HESr) namely Permixon(®) has demonstrated potent anti-inflammatory properties.
With the aim to provide new insight onto HESr anti-inflammatory properties in human we explore its effect on CPI biomarkers in men with lower urinary tract symptoms (LUTS) related to BPH using a non-invasive method and investigate links between biomarkers and clinical symptoms.
An international, randomized, double-blind, parallel-group, tamsulosin-controlled study was carried out in 206 men with BPH-related LUTS. Patients received oral daily HESr 320mg or tamsulosin 0. 4 mg during 3 months. The first urine stream after digital rectal examination (DRE) was collected at Day 1 and Day 90 and mRNA was extracted from prostatic epithelial cells desquaming in the lumen of the glands and seminal plasma fluid after DRE. mRNA quantification of the 29 most significant published inflammation markers in BPH and protein detection in urine was performed.
At D90, a decrease in mean gene expression was observed for 65. 4% of the markers detected in the HESr group versus 46. 2% in the tamsulosin group. In the 15 most frequently expressed genes, this difference was higher (80% vs. 33% respectively). Three proteins (MCP-1/CCL2, IP-10/CXCL10, and MIF) were detected. At D90, a decrease in the number of patients who expressed MCP-1/CCL2 and IP-10/CXCL10 was observed only in the HESr group. Moreover, MIF expression was significantly reduced by HESr compared with tamsulosin (P = 0. 007). Finally, in contrast to tamsulosin, the subgroup of patients treated by HESr and who over expressed MIF at baseline, had a higher response to the International Prostate Symptom Score (I-PSS) than those who did not over express this protein (mean I-PSS change: -6. 4 vs. -4. 5 respectively). As the study is exploratory, results should be confirmed in a powered clinical study.
These results showed for the first time at clinical level the anti-inflammatory properties of HESr, already indicated in BPH-related LUTS. Thus, HESr could be of interest to prevent unfavourable evolution in patients with CPI. Prostate 9999:XX-XX, 2015. © 2015 Wiley Periodicals, Inc.
The Prostate. 2015 Aug 26 [Epub ahead of print]
Alain Latil, Marie-Thérèse Pétrissans, Jérôme Rouquet, Grégoire Robert, Alexandre de la Taille
Institut de Recherche Pierre Fabre, Toulouse, France. , Institut de Recherche Pierre Fabre, Toulouse, France. , Institut de Recherche Pierre Fabre, Toulouse, France. , Department of Urology, Bordeaux Pellegrin University Hospital, Bordeaux, France. , Department of Urology and INSERM U955 Eq07, CHU Henri-Mondor, Créteil, France.